Shares of Lev Pharmaceuticals Inc. tumbled 33 percent after the FDA requested additional information - though likely no new trials - prior to an approval of Cinryze, the company's C1 inhibitor in hereditary angioedema. (BioWorld Today)

Robin Bellas is a partner in Morgenthaler Ventures (Menlo Park, California), a prominent life sciences venture capital firm. He joined Morgenthaler in 1983 after 10 years of management experience with emerging growth companies. Bellas has spearheaded the firm’s investment in life sciences companies and serves on the boards of 10 current portfolio companies, with previous service on the boards of numerous firms subsequently acquired by larger med-tech companies. (Biomedical Business & Technology)